2268.HK
WUXI XDC
HK$54.90
+3.98%
2026-05-29
About WUXI XDC
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Key Fundamentals
P/E Ratio
42.23
Forward P/E
21.67
EPS (TTM)
HK$1.30
ROE
17.1%
Revenue Growth (YoY)
35.9%
Profit Margin
24.9%
Debt/Equity
8.20
Price/Book
5.55
Beta
-0.76
Market Cap
HK$69.19B
Avg Volume (10D)
5.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$66.50
60D Low
HK$49.34
Avg Volume
4.6M
Latest Close
HK$54.90
Get breakout alerts for 2268.HK
Sign up for Breakout Scanner to receive daily notifications when 2268.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
WUXI XDC (2268.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2268.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2268.HK operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.